Circulating levels of carbamylated protein and neutrophil extracellular traps are associated with periodontitis severity in patients with rheumatoid arthritis: A pilot case-control study

Chihiro Kaneko¹, Tetsuo Kobayashi¹,²*, Satoshi Ito³, Noriko Sugita¹, Akira Murasawa³, Kiyoshi Nakazono³, Hiromasa Yoshie¹

¹ Division of Periodontology, Department of Oral Biological Science, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, ² General Dentistry and Clinical Education Unit, Niigata University Medical and Dental Hospital, Niigata, Japan, ³ Department of Rheumatology, Niigata Rheumatic Center, Shibata, Japan

* kotetsuo@dent.niigata-u.ac.jp

Abstract

Objectives

An interrelationship between rheumatoid arthritis (RA) and periodontitis has been suggested due to their common pathogenic mechanisms. Protein carbamylation and neutrophil extracellular traps (NETs) formation have been shown to be related to autoimmune conditions, including RA, but their association with periodontitis has not been elucidated. Therefore, we assessed whether or not circulating levels of carbamylated protein (CarP) and NETs are associated with periodontitis severity and influenced by periodontal treatment.

Methods

We conducted a retrospective case-control study that included 40 patients with RA and periodontitis, 30 patients with periodontitis, and 43 systemically and periodontally healthy controls to assess the circulating levels of CarP and NETs and rheumatologic and periodontal conditions. The same assessments were also performed in 22 patients with RA and periodontitis after 2 months of periodontal treatment, including oral hygiene instruction and full-mouth supragingival scaling.

Results

Patients with RA and periodontitis showed significantly higher serum levels of CarP and NETs than the control group (P = 0.04 and P < 0.001, respectively). The serum levels of CarP and NETs were significantly correlated positively with the mean values of probing depth (P = 0.01 and P = 0.007, respectively) and clinical attachment level (P = 0.007 and P = 0.001, respectively) in the 40 patients with RA and periodontitis. Multiple logistic regression analyses also revealed significantly positive associations between the serum levels of CarP and...
and NETs and moderate to severe periodontitis (P = 0.03 and P = 0.001, respectively). Furthermore, periodontal treatment significantly decreased the serum levels of CarP and NETs in patients with RA and periodontitis (P = 0.03 and P = 0.02).

**Conclusion**

The circulating levels of CarP and NETs are associated with periodontitis severity and influenced by periodontal treatment in patients with RA.

**Introduction**

Rheumatoid arthritis (RA) is a chronic inflammatory joint disease that causes damage to the cartilage and bone as well as disability [1]. The prevalence of RA in the world’s adult population is approximately 0.5% to 1.0% [2]. Periodontitis is also a chronic inflammatory disease that results from dysbiosis of oral microbiota, causing the loss of the connective tissue and alveolar bone support of the teeth [3]. The worldwide prevalence of severe periodontitis, as indicated by deep periodontal pockets of ≥ 6 mm, is 10% - 15% in adults [4]. A number of studies have suggested an epidemiological, serological, and clinical association between RA and periodontitis, which may be bi-directional in that RA affects the manifestation of periodontitis and, conversely, periodontitis is a risk factor for RA [5–7]. In addition, treatments for both diseases influence each other in that periodontal treatment improves the clinical and biochemical measures for RA [8], and targeted therapy for RA ameliorates the periodontal condition [9]. These observations imply that RA and periodontitis are interrelated through their common pathogenic mechanisms.

The majority of patients with RA (50% - 70%) are seropositive for autoantibodies against anti-cyclic citrullinated peptide (CCP) as well as for those against immunoglobulin G (IgG) known as rheumatoid factor (RF) [1]. Of these, anti-CCP autoantibodies play an important role in the pathophysiology of RA and thus constitute a specific biomarker that can be detected years before the onset of RA [1, 10]. In addition to citrullination, carbamylation, another post-translational modification of proteins, also produces autoantibodies that can trigger inflammatory conditions, including RA [11, 12]. Recent evidence has suggested that anti-carbamylated protein (CarP) antibodies may be useful as a diagnostic marker for RA but are independent of anti-CCP antibodies [13, 14]. Experimental arthritis studies have also shown that the appearance of anti-CarP antibodies in the sera precedes the onset of RA [15, 16]. Recently, the presence of CarP was also demonstrated in inflamed periodontal tissue from patients with mild to moderate periodontitis [17]. These findings led to the hypothesis that protein carbamylation in patients with RA may also be shared by periodontitis. However, no study has evaluated the relevance of circulating CarP levels to periodontitis or its severity.

Protein carbamylation is catalyzed by myeloperoxidase (MPO) released from neutrophils [11]. The critical role of neutrophils in innate immunity is well recognized by the phagocytosis of bacteria and formation of neutrophil extracellular traps (NETs). NETs are web-like structures that consist of chromatin backbones, histones, and antimicrobial proteins, including MPO [18]. Previous studies have indicated increased levels of NET generation and anti-CCP antibody production in the serum and synovial fluid from RA patients [19, 20]. These observations suggest that NETs may be a potential source of citrullinated proteins that are associated with autoimmune responses. However, other studies have also reported that MPO levels were elevated in the sera, salivary, and gingival crevicular fluid of patients with periodontitis.
compared with control individuals [21, 22]. NET formation is also detected in supragingival biofilms, gingival crevicular exudate, and inflamed periodontal tissue [23, 24]. These findings suggest that MPO-associated NETs may be a potential source of CarP in relation to periodontal inflammation, findings that conflict with those of another study [25]. It is therefore clinically important to determine whether or not circulating NETs levels are relevant to periodontitis and its severity.

The aim of the present study was to compare the circulating levels of CarP and NETs among patients with RA and periodontitis, patients with periodontitis only, and systemically and periodontally healthy controls. In addition, the relationship between the circulating levels of CarP and NETs and periodontitis severity was evaluated. Furthermore, the effect of periodontal treatment on the same biomarkers was also assessed in patients with RA and periodontitis.

Materials and methods

Ethics statement

The present study was approved by the Ethics Committee of Niigata University ( Permit Number 2017–0114) and Niigata Rheumatic Center (Permit Number 2017–009), which is in accordance with the Declaration of Helsinki and conformed to the STROBE (strengthening the reporting of observational studies in epidemiology) guidelines [26]. All participants provided their written informed consent to participate in the present study.

Study design and population

A retrospective case-control study was conducted at Niigata University Hospital and Niigata Rheumatic Center. The study applicants were 55 patients with RA and 86 with no signs of RA or other systemic diseases who were retrieved from 3 previous studies [27–29] (Fig 1). In brief, all applicants had undergone medical interviews that assessed their smoking status (never-smoker, former-smoker, or current-smoker), rheumatologic and periodontal examinations, and blood collections. Rheumatologists and periodontists evaluated each applicant independently and were blinded from each other regarding the rheumatologic and periodontal condition. All age, gender, smoking, rheumatologic, and periodontal data were extracted from the databases of the Niigata Rheumatic Center and Niigata University Hospital. RA was diagnosed by three licensed rheumatologists (SI, AM, and KN) according to the 1987 revised classification criteria of American Rheumatism Association [30] as well as the 2010 RA classification criteria of the American College of Rheumatology and European League Against Rheumatism [31]. Periodontitis was defined by one licensed periodontist (TK) based on the criteria of the Centers for Disease Control and Prevention (CDC)/American Academy of Periodontology (AAP) [32]. The eligibility criteria for patients with RA and those with periodontitis were having ≥ 15 teeth; the absence of diabetes mellitus, as assessed by HbA1c ≥ 6.5% and fasting plasma glucose ≥ 126 mg/dl [33]; the absence of pregnancy; and no history or the absence of any periodontal and antibiotic treatment within the previous 3 months. The eligibility criteria for the controls included systemically healthy individuals without periodontitis. Of these applicants, 15 for RA and 13 for non-RA who were lost to follow-up were excluded. Thus, the final analyzed study population included 40 patients with RA and periodontitis (RA+periodontitis group), 30 with periodontitis only (periodontitis group), and 43 control individuals (control group) (Fig 1).

Furthermore, of the 40 patients in the RA+periodontitis group, 22 had been randomly assigned to receive periodontal treatment including oral hygiene instruction and full-mouth supragingival scaling with ultrasonic instruments and were thus retrieved from a previous study [27]. All of the rheumatologic and periodontal data obtained before and after 2 months
of periodontal treatment (baseline and reassessment) were extracted from the databases as mentioned above.

### Periodontal examination

Clinical periodontal data were collected by one calibrated and licensed periodontist (TK) as previously described [28], including the number of teeth present, O’Leary’s plaque control record [34], bleeding on probing, probing depth, and clinical attachment level. The bleeding on probing, probing depth and clinical attachment level were measured at six sites around each tooth with a Williams probe (Hu-Friedy, Chicago, IL, USA). The reproducibility of the clinical measurements was calculated based on the intra-examiner intraclass correlation coefficient of 0.90. Periodontitis cases were defined as follows [32]: severe periodontitis, the presence of ≥ 2 proximal sites with a clinical attachment level of ≥ 6 mm (not on the same tooth) and at least 1 proximal site with a probing depth of ≥ 5 mm; moderate periodontitis, the presence of ≥ 2 proximal sites with a clinical attachment level of ≥ 4 mm, or ≥ 2 proximal sites with a probing depth of ≥ 5 mm (not on the same tooth); mild periodontitis, the presence of ≥ 2 proximal sites with a clinical attachment level of ≥ 3 mm, and ≥ 2 proximal sites with a probing depth of ≥ 4 mm (not on the same tooth) or 1 site with a probing depth of ≥ 5 mm. Participants who did not meet these criteria were considered not to have periodontitis.

### Rheumatologic examination

Clinical rheumatologic data were obtained by three licensed rheumatologists (SI, AM, KN) and stored in the Niigata Rheumatic Center database, which included the disease duration and
activity of RA, tender and swollen joint counts, and the patient’s general assessment of his/her condition scored on a visual analog scale (VAS). The disease activity of RA was determined with the Disease Activity Score including 28 joints using C-reactive protein (DAS28-CRP), which was calculated based on 4 components: the tender joint count, swollen joint count, VAS, and CRP measurements [35]. The serological rheumatologic data included anti-CCP IgG titers that were determined by an enzyme-linked immunosorbent assay (ELISA) with a commercially available kit (Medical & Biological Laboratories, Co., Ltd. Aichi, Japan) [36], and the serum levels RF and CRP that were measured with latex particle-enhanced and simple nephelometric methods (SRL, Tokyo, Japan), respectively. Positivity for anti-CCP IgG and RF was defined as measurements more than 4.5 U/mL and 15 IU/mL, respectively.

**Evaluation of serum CarP and NETs levels**

To evaluate the serum CarP levels, the quantity of carbamylated adduct in the serum samples was determined by a sandwich ELISA with a commercially available kit (Cell Biolabs Laboratories, INC. San Diego, CA) [37] according to the manufacturer’s instructions. For the evaluation of serum NETs levels, NETs-associated MPO-DNA complexes were quantified by an ELISA as described previously [38]. The brief protocol of detection for MPO-DNA complexes was as follows: 96-well microtiter plates were coated with 5 μg/ml of mouse anti-human MPO antibody (Bio-Rad Laboratories, Hercules, CA) overnight at 4˚C, blocked with 1% bovine serum albumin for 30 min at room temperature (RT), washed three times, incubated with serum samples (1:10 dilution) for 90 min at RT, washed three times, incubated with horseradish peroxidase-labeled anti-human DNA monoclonal antibody (Roche Diagnostics, Mannheim, Germany) for 90 min at RT, and underwent color development with 2,2’-Azino-bis (3-ethylbenzothiazoline-6-sulfonic acid) diaminonitromethane salt substrate for 20 min at RT, at which point the reaction was stopped. The optical absorbance was measured with a microplate reader (EMax Plus, Molecular Devices, LLC. Sunnyvale, CA) at 450 nm for CarP or at 405 nm for MPO-DNA complexes. Serum levels of CarP and NETs were expressed as ng/mL and ELISA units (EU), respectively.

**Statistical analyses**

The sample size calculation was performed using the SPSS software program (SamplePower version 3.0, IBM, Chicago, IL) based on the serum citrulline levels shown in a previous study [27]. The results revealed that having more than 20 patients in each group would exceed a statistical power of 0.8 with an alpha level of 5%. After evaluating the normality of distribution by Kolmogorov-Smirnov test, the differences in quantitative data among the groups were assessed by the Kruskal-Wallis test, followed by Scheffe’s test. Spearman’s rank correlation coefficient was used to determine the relationship between the serum levels of CarP and NETs and RA activity or periodontitis severity (mean probing depth and mean clinical attachment level) and among the serum levels of CarP, NETs, and anti-CCP IgG. Furthermore, the associations between the serum levels of CarP and NETs and periodontitis severity (healthy and mild periodontitis coded as 0, and moderate and severe periodontitis coded as 1) were assessed by multiple logistic regression analyses using a statistical software program (SPSS statistics version 21, IBM Japan, Tokyo, Japan). The possible covariates considered for the multiple logistic regression analyses were age, gender (male and female coded as 0 and 1), smoking status (never-smoker, former-smoker, and current-smoker coded as 0, 1, and 2), and the odds ratio (OR) and 95% confidence interval (95% CI) were calculated. The differences in quantitative data between the baseline and reassessment were assessed by Mann Whitney U-test. Statistical significance was considered to exist at 5% (P < 0.05).
Results

Comparison among the groups

The characteristics of the study population are presented in Table 1. No significant differences were observed among the groups in any demographic parameter values (P > 0.05) (Table 1). When compared to the control group, the RA+periodontitis group displayed significantly fewer teeth (P = 0.01) (Table 1), and both the RA+periodontitis and periodontitis groups showed significantly higher values of plaque control record, bleeding on probing, probing depth, and clinical attachment level as well as higher percentage of patients with moderate and severe periodontitis (P < 0.001 for all parameters) (Table 1). The RA+periodontitis group received medication with corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs),

Table 1. Characteristics of the study population.

| Parameter                      | RA+Periodontitis group (n = 40) | Periodontitis group (n = 30) | Control group (n = 43) | P-value |
|--------------------------------|---------------------------------|------------------------------|------------------------|---------|
| Demographic                    |                                 |                              |                        |         |
| Age, mean (SD) years           | 59.9 (13.3)                     | 55.5 (10.8)                  | 57.6 (9.5)             | 0.15    |
| Female, no. (SD) %             | 34 (85.0)                       | 25 (83.3)                    | 37 (86.0)              | 0.95    |
| Smoker of current/former/never, % | 0/35/65            |                              |                        |         |
| Periodontal                    |                                 |                              |                        |         |
| Teeth present, no. (SD)        | 24.9 (2.6)*                     | 25.4 (2.8)                   | 26.5 (2.2)             | 0.01    |
| Plaque control record, mean (SD) % | 51.7 (21.5)*                | 57.7 (16.5)*                | 17.3 (17.6)            | < 0.001 |
| Bleeding on probing, mean (SD) % | 15.8 (11.5)*                  | 18.1 (15.1)*                | 3.6 (6.3)              | < 0.001 |
| Probing depth, mean (SD) mm    | 2.9 (0.6)*                      | 2.9 (0.5)*                   | 2.2 (0.4)              | < 0.001 |
| Probing depth ≥ 4 mm, mean (SD) % | 22.6 (21.2)*                | 23.1 (9.4)*                  | 2.6 (0.3)              | < 0.001 |
| Clinical attachment level, mean (SD) mm | 3.1 (0.7)*                    | 3.2 (0.6)*                   | 2.3 (0.4)              | < 0.001 |
| Clinical attachment level ≥ 4 mm, mean (SD) % | 26.1 (23.2)               | 28.6 (9.4)*                   | 2.2 (0.4)              | < 0.001 |
| Periodontitis of no/mild/moderate/severe *, % | 0/20/33/47*                | 0/0/47/53*                  | 100/0/0/0              | < 0.001 |
| Rheumatologic                  |                                 |                              |                        |         |
| Disease duration, mean (SD) months | 12.0 (11.3)               | N/A                          | N/A                    |         |
| DAS28-CRP, mean (SD)           | 2.6 (0.8)                       | N/A                          | N/A                    |         |
| Remission/low/moderate/high activity (%) | 40/18/37/5               | N/A                          | N/A                    |         |
| Tender joint count, mean (SD)   | 1.1 (1.7)                       | N/A                          | N/A                    |         |
| Swollen joint count, mean (SD)  | 1.6 (2.3)                       | N/A                          | N/A                    |         |
| VAS, mean (SD) mm              | 27.5 (26.5)                     | N/A                          | N/A                    |         |
| Corticosteroid use, no. (%)     | 21 (52.5)                       | N/A                          | N/A                    |         |
| csDMARD use, no. (%)            | 28 (70.0)                       | N/A                          | N/A                    |         |
| bDMARD use, no. (%)             | 0 (0.0)                         | N/A                          | N/A                    |         |
| NSAID use, no (%)               | 7 (17.5)                        | N/A                          | N/A                    |         |
| Anti-CCP IgG level, mean (SD) U/mL | 139.7 (133.9)              | N/A                          | N/A                    |         |
| Anti-CCP IgG positive, no. (%)  | 31 (77.5)                       | N/A                          | N/A                    |         |
| RF level, mean (SD) IU/mL       | 70.6 (85.3)                     | N/A                          | N/A                    |         |
| RF positive, no. (%)            | 25 (62.5)                       | N/A                          | N/A                    |         |
| CRP level, mean (SD) mg/dL      | 0.4 (0.6)                       | N/A                          | N/A                    |         |

RA: rheumatoid arthritis; SD: standard deviation; N/A: not applicable; DAS28-CRP: disease activity score including 28 joints using C-reactive protein; VAS: visual analog scale; csDMARD: conventional synthetic disease-modifying antirheumatic drug; bDMARD: biological disease-modifying antirheumatic drug; NSAID: non-steroidal anti-inflammatory drug; CCP: cyclic citrullinated peptide; IgG: immunoglobulin G; RF: rheumatoid factor; EU: ELISA unit.

* Periodontitis case was defined according to the criteria of the Centers for Disease Control and Prevention /American Academy of Periodontology [30].
* The bold values are significantly different from those in the control group (P < 0.05).

https://doi.org/10.1371/journal.pone.0192365.t001
and conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) but not with any biological DMARDs (bDMARDs), including inhibitors of tumor necrosis factor, interleukin-6 receptor, and the co-stimulatory signal for T cell activation (Table 1). Univariate analyses revealed significantly higher serum CarP levels in the RA+periodontitis and periodontitis groups than in the control group (RA+periodontitis and periodontitis versus control: [mean ± standard deviation] 6.9 ± 17.2 ng/mL and 10.4 ± 20.8 ng/mL versus 0.1 ± 0.2 ng/mL, P = 0.04 and P = 0.004) (Fig 2A). The frequencies of individuals who had CarP in the serum samples were 32.5% in the RA+periodontitis group, 53.3% in the periodontitis group, and 7.0% in the control group. The serum NETs levels were significantly increased in the RA+periodontitis group compared to the periodontitis and control groups (RA+periodontitis versus periodontitis and control: 1.6 ± 0.5 EU versus 1.1 ± 0.3 EU and 1.0 ± 0.2 EU, P < 0.001 for both comparisons) (Fig 2B). The serum levels of both CarP and NETs were significantly correlated positively with the mean values of probing depth (P = 0.01 and P = 0.007, respectively) and those of the clinical attachment level (P = 0.007 and P = 0.001, respectively) in the 40 patients with RA and periodontitis (Fig 3A to 3D). Multiple logistic regression analyses also revealed that the serum levels of CarP and NETs were significantly associated with moderate to severe periodontitis (CarP: P = 0.03, OR = 2.05, 95% CI = 1.09 to 3.85; NETs: P = 0.001, OR = 14.49, 95% CI = 2.99 to 71.43) (Table 2). However, a significantly positive correlation was observed between the serum NETs levels and DAS28-CRP (P = 0.04) but not between the serum CarP levels and DAS28-CRP (P > 0.05) (Fig 4A and 4B). Furthermore, the serum CarP levels were not associated with the serum levels of NETs and anti-CCP IgG (P > 0.05) (Fig 5A and 5B), while the serum NETs levels were significantly correlated positively with the serum anti-CCP IgG levels (P = 0.007) (Fig 5C).

Comparison before and after periodontal treatment

In the 22 patients in the RA+periodontitis group who had received periodontal treatment, the distribution and dose of RA medication with corticosteroids, NSAIDs, or csDMARDs remained unchanged between the baseline and reassessment. Periodontal treatment significantly decreased the values of periodontal parameters, including the plaque control record,
bleeding on probing, probing depth, clinical attachment level, and percentage of patients with severe periodontitis ($P < 0.001$ for all parameters), as well as the DAS28-CRP and percentage of patients with moderate RA activities ($P = 0.02$ and $P = 0.04$) (Table 3). In addition, the treatment significantly reduced the serum levels of CarP and NETs (baseline versus reassessment: $11.7 \pm 21.8$ ng/mL versus $7.1 \pm 12.9$ ng/mL, $P = 0.03$ for CarP; $1.8 \pm 0.4$ EU versus $1.7 \pm 0.4$ EU, $P = 0.02$ for NETs) (Fig 6A and 6B).

![Fig 3. Relationship between serum CarP and NETs levels and mean values of probing depth and clinical attachment level in 40 patients with RA and periodontitis (A to D).](https://doi.org/10.1371/journal.pone.0192365.g003)

Serum CarP and NETs levels associated with periodontitis severity in RA

![Table 2. Significance of association between the baseline characteristics and periodontitis severity in the study population (n = 113).](https://doi.org/10.1371/journal.pone.0192365.t002)

| Parameter              | OR (95% CI)   | P-value |
|------------------------|---------------|---------|
| Age                    | 1.02 (0.98 to 1.07) | 0.32    |
| Women                  | 1.17 (0.24 to 5.71) | 0.85    |
| Former smoker          | 2.91 (0.75 to 11.24) | 0.12    |
| Serum CarP level       | 2.05 (1.09 to 3.85) | 0.03*   |
| Serum NETs level       | 14.49 (2.99 to 71.43) | 0.001*  |

CarP: carbamylated protein; NETs: neutrophil extracellular traps.

* Significantly associated with moderate and severe periodontitis ($P < 0.05$) (bold value).
Fig 4. Relationship between serum CarP and NETs levels and DAS28-CRP in 40 patients with RA and periodontitis (A and B). NS: no significant association.

https://doi.org/10.1371/journal.pone.0192365.g004

Fig 5. Relationship among serum levels of CarP, NETs, and anti-CCP IgG in 40 patients with RA and periodontitis (A to C). NS: no significant association.

https://doi.org/10.1371/journal.pone.0192365.g005
Discussion

The present pilot case-control study aimed to test the hypothesis that protein carbamylation and NETs formation in patients with RA may also be shared by periodontitis. The results of univariate analyses showed that the patients with RA and periodontitis exhibited significantly higher serum levels of CarP and NETs than the age-, gender-, smoking status-matched controls. These results suggest that the circulating levels of CarP and NETs were associated not only with RA but also periodontitis, which is supported by the findings described in other reports [39, 40]. In addition, the data indicated that the serum levels of CarP and NETs were significantly correlated positively with the mean values of the probing depth and clinical attachment level in patients with RA and periodontitis. Furthermore, the results of the multiple
regression analysis demonstrated that the serum levels of CarP and NETs were significantly associated with moderate to severe periodontitis. These findings suggest a positive association between the circulating levels of CarP and NETs and periodontitis severity. The elevation of circulating levels of CarP and NETs may reflect the increased concentration of MPO in the sera, salivary, gingival crevicular fluid, and periodontal tissue of in patients with periodontitis [39, 40]. To our knowledge, this is the first study to show that the circulating levels of CarP and NETs constitute a shared risk factor for RA and periodontitis, which may provide new insights into the underlying shared pathogenic mechanisms of RA and periodontitis.

Another objective of the present study was to evaluate the effect of periodontal treatment on the serum levels of CarP and NETs in patients with RA and periodontitis. The present results showed that periodontal treatment significantly decreased serum levels of CarP and NETs. The decrease in serum NETs levels is consistent with the results of another study that examined the changes in the NETs production derived from blood neutrophils before and after periodontal therapy [25]. These observations may reflect reduced levels of priming of circulating neutrophils after successful periodontal treatment. Likewise, the post-treatment decrease in the serum CarP levels might be due in part to the reduced release of MPO from neutrophils, as protein carbamylation is catalyzed by MPO [11]. The data also showed that the levels of periodontal tissue destruction, as determined by the probing depth and clinical attachment level, in patients with RA were significantly reduced by periodontal treatment. These observations support the possibility that circulating levels of CarP and NETs can constitute a novel biomarker associated with periodontitis severity in patients with RA and periodontitis. Furthermore, the results showed that periodontal treatment significantly decreased RA activity, which is consistent with the findings of our previous and another study [8, 27] which suggested the existence of an interrelationship between RA and periodontitis.

Interestingly, the results of the current study also indicated that the patients with only periodontitis had significantly higher circulating levels of CarP than the controls, which is supported by the findings of another study that showed the presence of CarP in inflamed periodontal tissue [17]. However, the serum NETs levels were comparable between the patients.

![Comparison of serum levels of (A) CarP and (B) NETs between the baseline and reassessment in patients with RA and periodontitis who received periodontal treatment.](https://doi.org/10.1371/journal.pone.0192365.g006)
with periodontitis and controls in the present study. These are consistent with the results of another study [25], which suggests the possibility of a recently reported self-protective mechanism within glutathione-deficient periodontitis neutrophils [41].

Another interesting note is that the serum NETs levels were significantly correlated with the RA activity in patients with RA and periodontitis. These findings are supported by the observations of another study that documented a potential association between NETs-derived products, including MPO and RA activity [42]. However, the results failed to show an association between the serum CarP levels and RA activity. The additional data indicated a significantly positive correlation between the serum levels of NETs and anti-CCP IgG in patients with RA and periodontitis. These results suggest that NETs may be a source of citrullinated proteins, and that elevated levels of circulating NETs may play a role in the progression of RA through protein citrullination. However, the data showed that the serum CarP levels were not associated with the serum levels of NETs and anti-CCP IgG. These observations suggest that NETs may not be a source of carbamylated proteins, which may be explained in part by the fact that many patients with RA and periodontitis exhibited no serum CarP.

The present study has some methodological limitations. First, the sample size was relatively small due to the strict eligibility criteria, resulting in this being only a pilot case-control study. Second, RA and periodontitis are complex diseases with multiple causal factors [1, 3, 5]. However, controlling for the confounding factors was restricted in the statistical analysis, as information on the risk factors was not fully available. Third, case-control studies are associated with some selection bias. However, data on the mean age and the percentage of females among patients with RA in the present study were similar to those of other large-scale race-matched cohort studies [35, 43], suggesting that the selection bias was minimal, although its possibility cannot be excluded. Fourth, we were unable to evaluate anti-CarP antibody and MPO due to the very limited amount of serum sample available. However, these evaluations will be necessary to validate whether or not RA and periodontitis have a specific interrelationship through protein carbamylation and NETs formation. Finally, we were unable to recruit any patients with RA who did not have periodontitis, possibly due to their extremely low numbers [8, 44]. However, it would be preferable to assess the shared risk factor for the two diseases in a study population including individuals with both diseases, individuals with either disease, and controls. As such, further studies in a large-scale cohort are required to confirm and extend the current observations.

In conclusion, the results of the present pilot case-control study showed for the first time that the circulating levels of CarP and NETs are associated with periodontitis severity in RA. These data may provide new insights into the underlying shared pathogenic mechanisms of RA and periodontitis. Further replication studies in a large-scale cohort are needed to confirm the current observations.

Supporting information
S1 Table. STROBE Checklist for the Case-Control study.

(DOCX)

Author Contributions
Conceptualization: Tetsuo Kobayashi.

Data curation: Tetsuo Kobayashi, Noriko Sugita.

Formal analysis: Chihiro Kaneko, Tetsuo Kobayashi.
Funding acquisition: Tetsuo Kobayashi.
Investigation: Chihiro Kaneko, Tetsuo Kobayashi.
Methodology: Tetsuo Kobayashi, Satoshi Ito.
Project administration: Tetsuo Kobayashi.
Resources: Tetsuo Kobayashi, Satoshi Ito, Noriko Sugita, Akira Murasawa, Kiyoshi Nakazono.
Software: Tetsuo Kobayashi.
Supervision: Hiromasa Yoshie.
Writing – original draft: Chihiro Kaneko, Tetsuo Kobayashi, Satoshi Ito.

References
1. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016; 388: 2023–2038. https://doi.org/10.1016/S0140-6736(16)30173-8 PMID: 27156434
2. Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev. 2005; 4: 130–136. https://doi.org/10.1016/j.autrev.2004.09.002 PMID: 15823498
3. Pihlstrom BL, Michalowicz BS, Johnson NW. Periodontal diseases. Lancet. 2005; 366: 1809–1820. https://doi.org/10.1016/S0140-6736(05)67728-8 PMID: 16298220
4. Petersen PE, Ogawa H. The global burden of periodontal disease: towards integration with chronic disease prevention and control. Periodontol 2000. 2012; 60: 15–39. https://doi.org/10.1111/j.1600-0757.2011.00425.x PMID: 22909104
5. de Pablo P, Chapple ILC, Buckley CD, Dietrich T. Periodontitis in systemic rheumatic diseases. Nat Rev Rheumatol. 2009; 5: 218–24. https://doi.org/10.1038/nrrheum.2009.28 PMID: 19337286
6. Lecch MT, Bartold PM. The association between rheumatoid arthritis and periodontitis. Best Pract Res Clin Rheumatol. 2015; 29: 199–201. https://doi.org/10.1016/j.berh.2015.03.001 PMID: 26362738
7. Potempa J, Mydel P, Koziel J. The case for periodontitis in the pathogenesis of rheumatoid arthritis. Nat Rev Rheumatol. 2017; 13: 606–620. https://doi.org/10.1038/nrrheum.2017.132 PMID: 28835673
8. Kaur S, Bright R, Proudman SM, Bartold PM. Does periodontal treatment influence clinical and biochemical measures for rheumatoid arthritis? A systematic review and meta-analysis. Semin Arthritis Rheum. 2014; 44: 113–122. https://doi.org/10.1016/j.semarthritis.2014.04.009 PMID: 24880982
9. Kobayashi T, Yoshie H. Host responses in the link between periodontitis and rheumatoid arthritis. Curr Oral Health Rep. 2015; 2: 1–8. https://doi.org/10.1007/s40496-014-0039-2 PMID: 25657893
10. Schellekens GA, de Jong BAW, van den Hoogen FHJ, van de Putte LBA, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest. 1998; 101: 273–281. https://doi.org/10.1172/JCI1316 PMID: 9421490
11. Wang Z, Nicholls SJ, Rodriguez ER, Kummu O, Hörkkö S, Barnard J, et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med. 2007; 13: 1176–1184. https://doi.org/10.1038/nm1637 PMID: 17828273
12. Shi J, Knevel R, Suwannalai P, van der Linden MP, Janssen GMC, van Veelen PA et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci U S A. 2011; 108: 17372–17377. https://doi.org/10.1073/pnas.1114465108 PMID: 21987702
13. Li L, Deng C, Chen S, Zhang S, Wu Z, Hu C et al. Meta-Analysis: Diagnostic accuracy of anti-carbamylated protein antibody for rheumatoid arthritis. PLoS One. 2016; 11: e0159000. https://doi.org/10.1371/journal.pone.0159000 PMID: 27437936
14. Montes A, Regueiro C, Perez-Pampin E, Boveda MD, Gomez-Reino JJ, Gonzalez A. Anti-carbamylated protein antibodies as a reproducible independent type of rheumatoid arthritis autoantibodies. PLoS One. 2016; 11: e0161141. https://doi.org/10.1371/journal.pone.0161141 PMID: 27537849
15. Stoop JN, Liu B-S, Shi J, Jansen DTS, Hegen M, Huizinga TWJ, et al. Antibodies specific for carbamylated proteins precede the onset of clinical symptoms in mice with collagen induced arthritis. PLoS One. 2014; 9: e102163. https://doi.org/10.1371/journal.pone.0102163 PMID: 25025869
16. Verheul MK, Vierboom MPM, † Hart BA, Toes REM, Trouw LA. Anti-carbamylated protein antibodies precede disease onset in monkeys with collagen-induced arthritis. Arthritis Res Ther. 2017; 19: 246. https://doi.org/10.1186/s13075-017-1455-1 PMID: 29096669
17. Bright R, Thiele GM, Manavis J, Mikulis TR, Payne JB, Bartold PM. Gingival tissue, an extrasynovial source of malondialdehyde-acetaldehyde adducts, citrullinated and carbamylated proteins. J Periodontal Res. 2017. Oct 17. https://doi.org/10.1111/jre.12486 PMID: 29044530

18. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhleman Y, Weiss DS, et al. Neutrophil extracellular traps kill bacteria. Science. 2004; 303: 1532–1535. https://doi.org/10.1126/science.1092385 PMID: 15001782

19. Khandpur R, Carmona-Rivera C, Vivekanandan-Giri A, Gizinski A, Yalavarthi S, Knight JS, et al. NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. Sci Transl Med. 2013; 5: 178ra40. https://doi.org/10.1126/scitranslmed.3005580 PMID: 23536012

20. Chowdhury CS, Giaglis S, Walker UA, Buser A, Hahn S, Hasler P. Enhanced neutrophil extracellular trap generation in rheumatoid arthritis: analysis of underlying signal transduction pathways and potential diagnostic utility. Arthritis Res Ther. 2014; 16: R122. https://doi.org/10.1186/ar4579 PMID: 24928093

21. Leppilahiti JM, Hernández-Rios PA, Gamonal JA, Tervahartiala T, Brignardello-Petersen R, Mantyla P, et al. Matrix metalloproteinases and myeloperoxidase in gingival crevicular fluid provide site-specific diagnosis value for chronic periodontitis. J Clin Periodontol. 2014; 41: 348–356. https://doi.org/10.1111/jcpe.12223 PMID: 24382144

22. Nizam N, Gümüş P, Pitkänen J, Tervahartiala T, Sorsa T, Buduneli N. Serum and salivary matrix metalloproteinases, neutrophil elastase, myeloperoxidase in patients with chronic or aggressive periodontitis. Inflammation. 2014; 37: 1171–1178. https://doi.org/10.1007/s10753-014-9907-0 PMID: 24799321

23. Vitokov L, Klappacher M, Hannig M, Krautgartner WD. Extracellular neutrophil traps in periodontitis. J Periodontal Res. 2009; 44: 664–672. https://doi.org/10.1111/j.1600-0765.2008.01175.x PMID: 19453857

24. Hirschfeld J, Domnisch H, Skora P, Horvath G, Latz E, Hoerauf A, et al. Neutrophil extracellular trap formation in subgingival biofilms. Int J Med Microbiol. 2015; 305: 453–463. https://doi.org/10.1016/j.ijmm.2015.04.002 PMID: 25959370

25. White P, Sakellari D, Roberts H, Risafsi I, Ling M, Cooper P et al. Peripheral blood neutrophil extracellular trap production and degradation in chronic periodontitis. J Clin Periodontol. 2016; 43: 1041–1049. https://doi.org/10.1111/jcpe.12628 PMID: 27678376

26. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007; 4: e296. https://doi.org/10.1371/journal.pmed.0040296 PMID: 17941714

27. Okada M, Kobayashi T, Ito S, Yokoyama T, Abe A, Murasawa A et al. Periodontal treatment decreases levels of antibodies to Porphyromonas gingivalis and citrulline in patients with rheumatoid arthritis and periodontitis. J Periodontol. 2013; 84: e74–e84. https://doi.org/10.1902/jop.2013.130079 PMID: 23701010

28. Shimada A, Kobayashi T, Ito S, Okada M, Murasawa A, Nakazono K, et al. Expression of anti-Porphyromonas gingivalis peptidylarginine deiminase immunglobulin G and peptidylarginine deiminase-4 in patients with rheumatoid arthritis and periodontitis. J Periodontal Res. 2016; 51: 103–111. https://doi.org/10.1111/jre.12288 PMID: 26094771

29. Kojima A, Kobayashi T, Ito S, Murasawa A, Nakazono K, Yoshie H. Tumor necrosis factor-alpha gene promoter methylation in Japanese patients with chronic periodontitis and rheumatoid arthritis. J Periodontal Res. 2016; 51: 350–358. https://doi.org/10.1111/jre.12314 PMID: 26247485

30. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper P, et al. The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988; 31: 315–324. PMID: 3358796

31. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. 2010 Rheumatoid arthritis classification criteria: an American college of rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheum. 2010; 62: 2569–2581. https://doi.org/10.1002/art.27584 PMID: 200701010

32. Eke PI, Page RC, Wei L, Thornton-Evans G, Genco RJ. Update of the case definitions for population-based surveillance of periodontitis. J Periodontol. 2012; 83: 1449–1454. https://doi.org/10.1902/jop.2012.110664 PMID: 22420873

33. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014; 37 (Suppl 1): S81–90. https://doi.org/10.2337/dc14-S081 PMID: 24357215

34. O’Leary TJ, Drake RB, Naylore JE. The plaque control record. J Periodontol. 1972; 43: 38. https://doi.org/10.1902/jop.1972.43.1.38 PMID: 4500182

35. Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N. Comparison of disease activity score (DAS) 28-erythrocyte sedimentation rate and DAS28-C-reactive protein threshold values. Ann Rheum Dis. 2007; 66: 407–409. https://doi.org/10.1136/ard.2006.054205 PMID: 16926186
36. Shidara K, Inoue E, Tanaka E, Hoshi D, Seto Y, Nakajima A, et al. Comparison of the second and third generation anti-cyclic citrullinated peptide antibody assays in the diagnosis of Japanese patients with rheumatoid arthritis. Rheumtol Int. 2011; 31: 617–22. https://doi.org/10.1007/s00296-009-1336-2 PMID: 20049446

37. Sun JT, Yang K, Lu L, Zhu ZB, Zhu JZ, Ni JW, et al. Increased carbamylation level of HDL in end-stage renal disease: carbamylated-HDL attenuated endothelial cell function. Am J Physiol Renal Physiol. 2016; 310: F511–517. https://doi.org/10.1152/ajprenal.00508.2015 PMID: 26764205

38. Wang H, Sha LL, Ma TT, Zhang LX, Chen M, Zhao MH. Circulating Level of Neutrophil Extracellular Traps Is Not a Useful Biomarker for Assessing Disease Activity in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. PLoS One. 2016; 11: e0148197. https://doi.org/10.1371/journal.pone.0148197 PMID: 26840412

39. Bright R, Proudman SM, Rosenstein ED, Bartold PM. Is there a link between carbamylation and citrullination in periodontal disease and rheumatoid arthritis? Medical Hypotheses. 2015; 84: 570–576. https://doi.org/10.1016/j.mehy.2015.03.006 PMID: 25801344

40. White PC, Chicca IJ, Cooper PR, Milward MR, Chapple ILC. Neutrophil extracellular traps in periodontitis: A web of intrigue. J Dent Res. 2016; 95: 26–34. https://doi.org/10.1177/0022034515609097 PMID: 26442948

41. Dias IHK, Chapple ILC, Milward M, Grant MM, Hill E, Brown J, et al. Sulforaphane restores cellular glutathione levels and reduces chronic periodontitis neutrophil hyperactivity in vitro. PLoS One. 2013; 8: e66407. https://doi.org/10.1371/journal.pone.0066407 PMID: 23826097

42. Pérez-Sánchez C, Ruiz-Limón P, Aguirre MA, Jiménez-Gómez Y, Arias-de la Rosa I, Ábalos-Aguilera MC, et al. Diagnostic potential of NETosis-derived products for disease activity, atherosclerosis and therapeutic effectiveness in rheumatoid arthritis patients. J Autoimmun. 2017; 82: 31–40. https://doi.org/10.1016/j.jaut.2017.04.007 PMID: 28465139

43. Matsui T, Kuga Y, Kaneko A, Nishino J, Eto Y, Chiba N, et al. Disease activity score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan. Ann Rheum Dis. 2007; 66: 1221–1226. https://doi.org/10.1136/ard.2006.063834 PMID: 17369281

44. Kobayashi T, Ito S, Kuroda T, Yamamoto K, Sugita N, Narita I, et al. The interleukin-1 and Fcγ receptor gene polymorphisms in Japanese patients with rheumatoid arthritis and periodontitis. J Periodontol. 2007; 78: 2311–2318. https://doi.org/10.1902/jop.2007.070136 PMID: 18052703